Schrödinger, Inc. in 1 story
The narratives SDGR currently appears in, with its side and exposure in each.
Bull side
0 storiesNo bull-side stories for SDGR yet.
Bear side
1 story- China Becomes Pharma's Global R&D Engine
SDGR in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Schrodinger's premium computational-discovery model faces a tougher value benchmark if Chinese developers can deliver clinically validated molecules faster and at lower total cost.